JP2016514091A - トランスサイレチン抗体およびその使用 - Google Patents

トランスサイレチン抗体およびその使用 Download PDF

Info

Publication number
JP2016514091A
JP2016514091A JP2015557148A JP2015557148A JP2016514091A JP 2016514091 A JP2016514091 A JP 2016514091A JP 2015557148 A JP2015557148 A JP 2015557148A JP 2015557148 A JP2015557148 A JP 2015557148A JP 2016514091 A JP2016514091 A JP 2016514091A
Authority
JP
Japan
Prior art keywords
ttr
mutation
antibody
subject
native
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015557148A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514091A5 (cg-RX-API-DMAC7.html
Inventor
シン ジャン,
シン ジャン,
ジェフリー ダブリュー. ケリー,
ジェフリー ダブリュー. ケリー,
ジャスティン チャプマン,
ジャスティン チャプマン,
Original Assignee
ミスフォールディング ダイアグノスティクス, インコーポレイテッド
ミスフォールディング ダイアグノスティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミスフォールディング ダイアグノスティクス, インコーポレイテッド, ミスフォールディング ダイアグノスティクス, インコーポレイテッド filed Critical ミスフォールディング ダイアグノスティクス, インコーポレイテッド
Publication of JP2016514091A publication Critical patent/JP2016514091A/ja
Publication of JP2016514091A5 publication Critical patent/JP2016514091A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015557148A 2013-02-08 2014-02-07 トランスサイレチン抗体およびその使用 Pending JP2016514091A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361762750P 2013-02-08 2013-02-08
US61/762,750 2013-02-08
US201361863818P 2013-08-08 2013-08-08
US61/863,818 2013-08-08
PCT/US2014/015421 WO2014124334A2 (en) 2013-02-08 2014-02-07 Transthyretin antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2016514091A true JP2016514091A (ja) 2016-05-19
JP2016514091A5 JP2016514091A5 (cg-RX-API-DMAC7.html) 2017-03-02

Family

ID=51300272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015557148A Pending JP2016514091A (ja) 2013-02-08 2014-02-07 トランスサイレチン抗体およびその使用

Country Status (4)

Country Link
US (2) US9790269B2 (cg-RX-API-DMAC7.html)
EP (1) EP2953970A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016514091A (cg-RX-API-DMAC7.html)
WO (1) WO2014124334A2 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020188700A (ja) * 2019-05-21 2020-11-26 国立大学法人 熊本大学 アミロイドーシス治療薬の新規スクリーニング方法及びアミロイドーシスのための医薬組成物
JP2020536532A (ja) * 2017-10-06 2020-12-17 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
US11873332B2 (en) 2017-11-29 2024-01-16 Novo Nordisk A/S Lyophilized formulation of a monoclonal antibody against transthyretin
US11912759B2 (en) 2015-01-28 2024-02-27 Novo Nordisk A/S Anti-transthyretin antibodies
US12247985B2 (en) 2017-10-06 2025-03-11 Novo Nordisk A/S Methods of detecting transthyretin

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160168235A1 (en) * 2013-07-19 2016-06-16 Board Of Regents Of The University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
PE20161093A1 (es) 2013-12-20 2016-10-23 Neurimmune Holding Ag Terapia basada en anticuerpos de amiloidosis por transtiretina (ttr) y anticuerpos derivados de humanos de la misma
JP6517156B2 (ja) * 2014-01-29 2019-05-22 Kmバイオロジクス株式会社 抗トランスサイレチンヒト抗体
CN106574258B (zh) * 2014-01-29 2021-03-30 Km生物医药股份公司 抗-运甲状腺素蛋白人源化抗体
TWI718121B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI769570B (zh) * 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
TWI786505B (zh) * 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
JP7017013B2 (ja) * 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
JP7016470B2 (ja) * 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
EP3478714A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
JP6792066B2 (ja) * 2016-09-10 2020-11-25 エルジー エレクトロニクス インコーポレイティド 無線通信システムにおいてセンシング区間の間に送信が行われたサブフレームに関連するサブフレームを除外したサブフレームを選択区間で選択する方法及び上記方法を利用する端末
KR102668318B1 (ko) * 2016-09-19 2024-05-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 지카바이러스에 대항하는 신규한 백신 및 지카바이러스에 대해 사용하기 위한 dna 항체 작제물의 조합
WO2019241497A1 (en) * 2018-06-13 2019-12-19 The Wistar Institute Of Anatomy And Biology Dna antibody constructs for use against zika virus
EP3876713B1 (en) 2018-11-09 2024-10-02 Neurimmune AG Patient-derived amyloid xenograft rodent model
MX2021014682A (es) * 2019-05-31 2022-04-06 Plex Pharmaceuticals Inc Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
CN112568961B (zh) 2019-09-27 2025-07-01 巴德阿克塞斯系统股份有限公司 骨内装置的自动推进特征
WO2021120937A1 (zh) * 2019-12-17 2021-06-24 童妍(上海)医疗器械有限公司 转甲状腺素蛋白进入眼内以及在制备滴剂中的应用
CN215349256U (zh) 2020-04-21 2021-12-31 巴德阿克塞斯系统股份有限公司 骨内进入装置及进入装置
EP4606330A3 (en) 2020-06-03 2025-11-05 Bard Access Systems, Inc. Intraosseous device including a sensing obturator
CN114098918B (zh) 2020-08-25 2025-12-12 巴德阿克塞斯系统股份有限公司 成角度的骨内进入系统
US12551236B2 (en) 2020-09-01 2026-02-17 Bard Access Systems, Inc. Retractable intraosseous access system
EP4203820B1 (en) * 2020-09-09 2025-01-29 Bard Access Systems, Inc. Aspiration apparatus for intraosseous access system
CN117062527A (zh) 2021-01-19 2023-11-14 埃里莫斯制药有限责任公司 作为冠状病毒抗病毒剂的Terameprocol和去甲二氢愈创木酸(NDGA)衍生物
EP4287952A1 (en) 2021-02-08 2023-12-13 Bard Access Systems, Inc. Intraosseous modular power
CN117916599A (zh) 2021-09-07 2024-04-19 美国西门子医学诊断股份有限公司 生物标记物组合物及其使用方法
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
EP4296279A1 (en) * 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin (ttr) binding proteins and uses thereof
CN120457342A (zh) 2022-12-05 2025-08-08 神经免疫有限公司 环状化合物及环状化合物在用于检测抗体的测定中的用途
CN116396392B (zh) * 2023-01-17 2023-10-27 珠海重链生物科技有限公司 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用
SE2350342A1 (en) * 2023-03-27 2024-09-28 Anders Olofsson Composition for use in prevention and/or treatment of human transthyretin amyloidosis
JP2026516527A (ja) * 2023-05-19 2026-05-25 ニューリミューン アーゲー 筋骨格障害及び状態のための新規免疫療法
JP2026521167A (ja) 2023-06-07 2026-06-26 ニューリミューン アーゲー アミロイドーシス治療用ワクチン
KR20260113091A (ko) 2023-11-15 2026-07-21 뉴리뮨 아게 항-트랜스티레틴 항체, 상기 항체를 포함하는 조성물 및 트랜스티레틴-매개 아밀로이드증의 치료 또는 예방 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010195710A (ja) * 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5156965A (en) 1983-11-29 1992-10-20 Igen, Inc. Catalytic antibodies
CH668554A5 (de) 1984-04-09 1989-01-13 Sandoz Ag Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
ATE68968T1 (de) 1985-11-22 1991-11-15 Takeda Chemical Industries Ltd Liposomzusammensetzung.
JP2666345B2 (ja) 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
CA2045129A1 (en) 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US5658753A (en) 1989-04-25 1997-08-19 Paul; Sudhir Catalytic antibody components
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP0549723A1 (en) 1990-09-21 1993-07-07 Chiron Corporation Packaging cells
ATE188740T1 (de) 1991-02-19 2000-01-15 Univ California Viruspartikel mit veraendertem wirtspektrum
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
AU3972893A (en) 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
AU7353494A (en) 1993-11-12 1995-05-29 Case Western Reserve University Episomal expression vector for human gene therapy
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えdnaウイルスおよびその製造方法
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997026919A2 (en) 1996-01-24 1997-07-31 Warner-Lambert Company Method of imaging amyloid deposits
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US6472436B1 (en) 2000-07-17 2002-10-29 The Salk Institute For Biological Studies Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
CA2444214A1 (en) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
JP4351043B2 (ja) 2001-07-09 2009-10-28 エラン ファーマシューティカルズ,インコーポレイテッド アミロイド毒性の阻害方法
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
DK1587821T6 (da) 2002-12-19 2025-05-26 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
EA013225B1 (ru) 2003-01-07 2010-04-30 Симфоген А/С Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
US20060035946A1 (en) 2003-01-22 2006-02-16 The General Hospital Corporation Amyloid-binding, metal-chelating agents
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
ES2332524T3 (es) 2004-07-20 2010-02-08 Symphogen A/S Un procedimiento para la caracterizacion de una linea celular policlonal.
EP1930046A1 (en) 2004-12-08 2008-06-11 Sirion Therapeutics, Inc. Retinol binding protein and transthyretin modulators for treating diabetes
US20070111258A1 (en) 2005-06-22 2007-05-17 Kaufman Randal J Compositions and methods for modulating the acute phase response
EP1921916A2 (en) 2005-08-11 2008-05-21 The Scripps Research Institute Genistein inhibition of transthyretin amyloidosis
EP2023919A4 (en) 2006-05-08 2010-12-22 Molecular Neuroimaging Llc COMPOUNDS AND AMYLOID PROBES FOR THERAPY AND IMAGING USES
US20100159486A1 (en) * 2006-11-01 2010-06-24 George Mason Intellectual Properties, Inc. Biomarkers for neurological conditions
WO2008141074A1 (en) 2007-05-10 2008-11-20 Salk Institute For Biological Studies Identification of compounds that protect against amyloid diseases
BRPI0812091A2 (pt) 2007-05-25 2014-10-14 Symphogen As Método para fabricar uma proteína policlonal recombinante
US20090123373A1 (en) 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
WO2009065414A1 (en) 2007-11-22 2009-05-28 Symphogen A/S A method for characterization of a recombinant polyclonal protein
WO2010030203A1 (en) * 2008-09-09 2010-03-18 Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr
EP2342220B1 (en) * 2008-10-06 2021-05-12 The University Of British Columbia Methods and systems for predicting misfolded protein epitopes
WO2010045384A2 (en) 2008-10-15 2010-04-22 Somagenics Inc. Short hairpin rnas for inhibition of gene expression
EP2937418B1 (en) 2008-10-20 2017-10-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
CA2749163A1 (en) 2009-01-14 2010-07-22 The Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases
JP5723378B2 (ja) 2009-11-03 2015-05-27 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. トランスサイレチン(ttr)を阻害する脂質製剤化組成物及び方法
WO2011100396A2 (en) 2010-02-10 2011-08-18 Trustees Of Boston University Serum clusterin levels in systemic amyloidosis featuring cardiomyopathy
US20130281510A1 (en) 2010-03-29 2013-10-24 Kumamoto University siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
EP2566333A4 (en) 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010195710A (ja) * 2009-02-25 2010-09-09 Kumamoto Univ アミロイド線維形成抑制剤及びその利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROC. NATL. ACAD. SCI. U S A., vol. 96, no. 6, JPN6017049921, 16 March 1999 (1999-03-16), pages 3108 - 3113, ISSN: 0003913330 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912759B2 (en) 2015-01-28 2024-02-27 Novo Nordisk A/S Anti-transthyretin antibodies
JP2020536532A (ja) * 2017-10-06 2020-12-17 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
JP7357609B2 (ja) 2017-10-06 2023-10-06 ノボ ノルディスク エー/エス 抗トランスサイレチン抗体
US12247985B2 (en) 2017-10-06 2025-03-11 Novo Nordisk A/S Methods of detecting transthyretin
US11873332B2 (en) 2017-11-29 2024-01-16 Novo Nordisk A/S Lyophilized formulation of a monoclonal antibody against transthyretin
JP2020188700A (ja) * 2019-05-21 2020-11-26 国立大学法人 熊本大学 アミロイドーシス治療薬の新規スクリーニング方法及びアミロイドーシスのための医薬組成物
JP7360142B2 (ja) 2019-05-21 2023-10-12 国立大学法人 熊本大学 アミロイドーシス治療薬の新規スクリーニング方法

Also Published As

Publication number Publication date
US20180022797A1 (en) 2018-01-25
US20160039916A1 (en) 2016-02-11
EP2953970A4 (en) 2016-06-29
US9790269B2 (en) 2017-10-17
WO2014124334A2 (en) 2014-08-14
WO2014124334A3 (en) 2014-12-24
EP2953970A2 (en) 2015-12-16

Similar Documents

Publication Publication Date Title
US9790269B2 (en) Transthyretin antibodies and uses thereof
JP7244600B2 (ja) 過リン酸化タウに特異的な抗体およびその使用方法
JP6050124B2 (ja) Wntシグナル伝達経路を阻害するモノクローナル抗体ならびにその製造方法およびその使用方法
JP5475994B2 (ja) 抗Aβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
JP6345655B2 (ja) タウに対する抗体
Chukwu et al. Tau antibody structure reveals a molecular switch defining a pathological conformation of the tau protein
Kabayama et al. An ultra-stable cytoplasmic antibody engineered for in vivo applications
SG183854A1 (en) Oligomer-specific amyloid beta epitope and antibodies
JP2010530735A (ja) 細胞内のprl−1ポリペプチドまたはprl−3ポリペプチドに結合する抗体
CN106574258A (zh) 抗‑运甲状腺素蛋白人源化抗体
TW201542589A (zh) 偵測人類periostin之新穎分析法
JP5654989B2 (ja) グッドパスチャー抗原結合タンパク質およびその検出
JPWO2020032027A1 (ja) アルツハイマー病の判定薬および判定方法
US20220363738A1 (en) Method
JP2012507003A (ja) チトクロームcアセチル化の検出及び調節
WO2023208119A1 (zh) 作为早老性痴呆诊断标志物的ddit4l剪切产物
Zhang et al. Single chain variable fragment against Aβ expressed in baculovirus inhibits Abeta fibril elongation and promotes its disaggregation
WO2023034324A2 (en) Methods and materials to treat neurodegenerative disease
US20140271463A1 (en) Bri2 as a novel biomarker for alzheimer's disease
JP5971966B2 (ja) Tdp−43の凝集体が蓄積する疾患の発症リスクを予測する方法、診断薬及び治療薬
US20240352102A1 (en) Compositions for treating tauopathies and methods of use thereof
Köppen et al. Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis
US20110027288A1 (en) Human monoclonal antibodies against amyloid beta protein, and their use as therapeutic agents
Class et al. Patent application title: BRI2 AS A NOVEL BIOMARKER FOR ALZHEIMER'S DISEASE Inventors: Marta Del Campo Milan (Amsterdam, NL) Cornelia Ramona Jimenez (Amsterdam, NL) Chrlott Elisabeth Teunissen (Amsterdam, NL) Assignees: Stichting VU-VUmc
JP2024009473A (ja) 筋炎/皮膚筋炎やそれに併発する間質性肺炎を発症するモデル動物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181105